Johnson & Johnson Pharmaceutical Research & Development, L.L.C. clinical trials

A subsidiary of Johnson & Johnson

The registry lists 465 studies whose lead sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jun 29, 2023.

Studies

Recruiting first, then most recently updated. Showing 50 of 465. List all 465 → · All Johnson & Johnson studies →

• A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult ParticipantsCompletedNCT04330248Phase 1

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder PainTerminatedNCT01060254Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From OsteoarthritisTerminatedNCT01094262Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related PainTerminatedNCT00973141Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or PneumoniaCompletedNCT00515034Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese VolunteersCompletedNCT01756404Phase 1

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00097981Phase 3

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• Study of Abiraterone Acetate in Patients With Advanced Prostate CancerApproved for marketingNCT01217697

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• An Efficacy and Safety Study of Prucalopride in Participants With Chronic ConstipationCompletedNCT01116206Phase 3

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy SubjectsCompletedNCT00602589Phase 1

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Evaluate the Effect of Food on Levofloxacin Pharmacokinetics From an Oral Solution FormulationCompletedNCT00601432Phase 1

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Evaluate the Pharmacokinetic Drug Interaction Between Multiple Doses of JNJ-31001074 and a Single Dose of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in WomenWithdrawnNCT00915668Phase 1

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)WithdrawnNCT00446602Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Evaluate Folate Levels in Women Taking Oral ContraceptivesWithdrawnNCT00301587Phase 3

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)CompletedNCT00093990Phase 3

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With DiabetesCompletedNCT01235260

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian VolunteersCompletedNCT01748526Phase 1

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of DomperidoneCompletedNCT00925457

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.CompletedNCT00511784

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth ControlCompletedNCT00377988

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart AttacksCompletedNCT00331071

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male VolunteersCompletedNCT01791231Phase 1

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)CompletedNCT01787357Phase 1

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy VolunteersCompletedNCT01756417Phase 1

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back PainTerminatedNCT00973024Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful NeuropathyTerminatedNCT00993018Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)TerminatedNCT00964990Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Evaluate the Effectiveness of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge ModelCompletedNCT01241422Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)CompletedNCT00796120Phase 3

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Observe the Number of Patients Who Develop Pure Red Cell Aplasia (PRCA, a Rare Form of Anemia) While Receiving Epoetin Alfa or Other Recombinant ErythropoietinsCompletedNCT00211029

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in AdultsCompletedNCT00604123Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back PainCompletedNCT00594516Phase 3

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I DisorderCompletedNCT00490971Phase 3

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With BortezomibWithdrawnNCT00706953Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another ErythropoietinCompletedNCT00210951

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and OlderTerminatedNCT00082095Phase 3

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney FailureCompletedNCT00391287

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary SyndromeCompletedNCT00809965Phase 3

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced CancerCompletedNCT00060944Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Safety and Effectiveness Study of JNJ-18038683 in Patients With Moderate to Severe DepressionCompletedNCT00566202Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 DiabetesCompletedNCT00672386Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian CancerCompletedNCT00113607Phase 3

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study of Effect of Food on the Pharmacokinetics of a Single JNJ-39823277 (TPI-1062) Dose in Healthy ParticipantsCompletedNCT02103985Phase 1

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With SchizophreniaCompletedNCT00589914Phase 3

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.CompletedNCT00111189Phase 3

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I DisorderCompletedNCT00309699Phase 3

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.TerminatedNCT00530166Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• An Efficacy and Safety Study of One Dosage of Paliperidone Extended Release (ER) in Treating Patients With SchizophreniaCompletedNCT00524043Phase 4

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral NeuropathyTerminatedNCT00267007Phase 2

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

• Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With SchizophreniaCompletedNCT00590577Phase 3

  Sponsor listed in the registry: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.